AGL 31.35 Increased By ▲ 0.15 (0.48%)
AIRLINK 143.00 Increased By ▲ 0.30 (0.21%)
BOP 5.12 Increased By ▲ 0.04 (0.79%)
CNERGY 4.11 Increased By ▲ 0.07 (1.73%)
DCL 9.49 Decreased By ▼ -0.21 (-2.16%)
DFML 49.51 Decreased By ▼ -0.69 (-1.37%)
DGKC 79.10 Decreased By ▼ -0.40 (-0.5%)
FCCL 22.75 Decreased By ▼ -0.30 (-1.3%)
FFBL 46.78 Increased By ▲ 0.68 (1.48%)
FFL 9.57 Increased By ▲ 0.52 (5.75%)
HUBC 153.49 Decreased By ▼ -0.01 (-0.01%)
HUMNL 11.29 Decreased By ▼ -0.18 (-1.57%)
KEL 4.17 Increased By ▲ 0.03 (0.72%)
KOSM 9.26 Decreased By ▼ -1.01 (-9.83%)
MLCF 33.30 Decreased By ▼ -0.30 (-0.89%)
NBP 58.70 Increased By ▲ 1.85 (3.25%)
OGDC 136.75 Decreased By ▼ -0.50 (-0.36%)
PAEL 25.88 Increased By ▲ 1.43 (5.85%)
PIBTL 6.05 Increased By ▲ 0.08 (1.34%)
PPL 112.35 Decreased By ▼ -0.65 (-0.58%)
PRL 24.38 Increased By ▲ 0.03 (0.12%)
PTC 11.88 Decreased By ▼ -0.07 (-0.59%)
SEARL 57.40 Decreased By ▼ -0.36 (-0.62%)
TELE 7.77 Increased By ▲ 0.17 (2.24%)
TOMCL 41.99 Increased By ▲ 0.11 (0.26%)
TPLP 8.49 Decreased By ▼ -0.16 (-1.85%)
TREET 15.23 Increased By ▲ 0.13 (0.86%)
TRG 51.50 Decreased By ▼ -0.95 (-1.81%)
UNITY 28.00 Increased By ▲ 0.14 (0.5%)
WTL 1.42 Increased By ▲ 0.08 (5.97%)
BR100 8,340 Decreased By -5.8 (-0.07%)
BR30 26,956 Increased By 47.9 (0.18%)
KSE100 78,898 Increased By 34.4 (0.04%)
KSE30 25,008 Decreased By -18.2 (-0.07%)

NEW YORK: The US Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech Covid-19 vaccine for children aged between 12 and 15 years, and narrowed the time for all booster shots to 5 months from 6 months after primary doses.

The agency also authorized a third shot in children aged 5 through 11 years who are immunocompromised. The FDA said it reviewed published data and real world evidence on the safety of booster doses provided by the Israeli Ministry of Health including data from over 6,300 individuals 12-to-15 years of age who received a Pfizer shot.

Global COVID-19 cases are surging due to the Omicron variant and health authorities have warned that its extremely high transmissibility could overwhelm many health systems. Laboratory tests have shown that two doses of the Pfizer-BioNTech and Moderna vaccines generate low immune responses against Omicron, while boosters appear to be protective against the highly-mutated variant.

Comments

Comments are closed.